logo

ARGX

argenx·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

ARGX fundamentals

argenx (ARGX) released its earnings on Oct 30, 2025: revenue was 1.15B (YoY +100.70%), beat estimates; EPS was 5.18 (YoY +272.66%), beat estimates.
Revenue / YoY
1.15B
+100.70%
EPS / YoY
5.18
+272.66%
Report date
Oct 30, 2025
ARGX Earnings Call Summary for Q3,2025
  • Revenue milestone: $1.13B Q3 product sales, 96% YoY growth, fueled by PFS adoption in gMG and CIDP.
  • Pipeline acceleration: 3 Phase III assets advancing, with Graves' disease trial set for 2026 and 4 new Phase I molecules by year-end.
  • Financial strength: $4.3B cash balance, 11% gross margin, and disciplined expense growth (~$2.6B for 2025).
  • Strategic focus: Seronegative gMG (60% MSE in Phase II) and CIDP expansion, with Graves' disease as next frontier in thyroid autoimmunity.
EPS
Revenue

Revenue & Expenses

ARGX has released its 2025 Q3 earnings report, with revenue of 1.15B, reflecting a YoY change of 95.51%, and net profit of 344.26M, showing a YoY change of 276.61%. The Sankey diagram below clearly presents ARGX's revenue sources and cost distribution.

Key Indicators

argenx (ARGX) key financial stats and ratios, covering profitability, financial health, and leverage.
argenx (ARGX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
argenx (ARGX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
argenx (ARGX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does argenx (ARGX) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track argenx (ARGX) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield